Linked Life Data

9282824

Source:http://linkedlifedata.com/resource/pubmed/id/9282824

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9282824rdf:typepubmed:Citationlld:pubmed
pubmed-article:9282824lifeskim:mentionsumls-concept:C0019169lld:lifeskim
pubmed-article:9282824lifeskim:mentionsumls-concept:C0042769lld:lifeskim
pubmed-article:9282824lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:9282824lifeskim:mentionsumls-concept:C0279030lld:lifeskim
pubmed-article:9282824lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:9282824lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:9282824lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:9282824lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:9282824lifeskim:mentionsumls-concept:C1554184lld:lifeskim
pubmed-article:9282824pubmed:issue8lld:pubmed
pubmed-article:9282824pubmed:dateCreated1997-10-23lld:pubmed
pubmed-article:9282824pubmed:abstractTextPatients with dual infection with hepatitis B virus (HBV) and delta virus (HDV) responded poorly to interferon (IFN) therapy. Little is known about the effect of IFN therapy in patients with HBV and hepatitis C virus (HCV) dual infection. The patients in two randomized controlled trials with chronic HBV infection were retrospectively assayed for HCV markers. The HBV responses to IFN therapy in patients with and without HCV markers were compared. An open trial was conducted in 4 patients who had lost their serum HBV surface antigen (HBsAg) but had continuing HCV viremia and hepatitis. Of the 15 patients seropositive for HCV marker(s), only 1 (6.7%) responded with seroclearance of HBV DNA and HBV e antigen, as compared with 46 (28%) of 164 HCV-negative patients (p = 0.058). Icteric hepatitis developed in 1 patient on emergence of serum HCV RNA in association with seroclearance of HBV DNA. In contrast, good response was demonstrated in 3 of the 4 patients who had lost serum HBsAg before therapy. The results suggest that IFN therapy is not only of limited value in patients with dual infection with HBV and HCV but also has a potential risk of severe hepatitis if the clearance of one virus removes its suppressive effect on and facilitates the emergence of the other. However, patients with continuing HCV hepatitis after termination of the chronic HBsAg carrier state responded well to IFN therapy.lld:pubmed
pubmed-article:9282824pubmed:languageenglld:pubmed
pubmed-article:9282824pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9282824pubmed:citationSubsetIMlld:pubmed
pubmed-article:9282824pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9282824pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9282824pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9282824pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9282824pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9282824pubmed:statusMEDLINElld:pubmed
pubmed-article:9282824pubmed:monthAuglld:pubmed
pubmed-article:9282824pubmed:issn1079-9907lld:pubmed
pubmed-article:9282824pubmed:authorpubmed-author:LiawY FYFlld:pubmed
pubmed-article:9282824pubmed:authorpubmed-author:LinS MSMlld:pubmed
pubmed-article:9282824pubmed:authorpubmed-author:ChoC GCGlld:pubmed
pubmed-article:9282824pubmed:authorpubmed-author:SheenI SISlld:pubmed
pubmed-article:9282824pubmed:authorpubmed-author:ChienR NRNlld:pubmed
pubmed-article:9282824pubmed:authorpubmed-author:TsaiS LSLlld:pubmed
pubmed-article:9282824pubmed:authorpubmed-author:ZhuB JBJlld:pubmed
pubmed-article:9282824pubmed:issnTypePrintlld:pubmed
pubmed-article:9282824pubmed:volume17lld:pubmed
pubmed-article:9282824pubmed:ownerNLMlld:pubmed
pubmed-article:9282824pubmed:authorsCompleteYlld:pubmed
pubmed-article:9282824pubmed:pagination449-52lld:pubmed
pubmed-article:9282824pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:9282824pubmed:meshHeadingpubmed-meshheading:9282824-...lld:pubmed
pubmed-article:9282824pubmed:meshHeadingpubmed-meshheading:9282824-...lld:pubmed
pubmed-article:9282824pubmed:meshHeadingpubmed-meshheading:9282824-...lld:pubmed
pubmed-article:9282824pubmed:meshHeadingpubmed-meshheading:9282824-...lld:pubmed
pubmed-article:9282824pubmed:meshHeadingpubmed-meshheading:9282824-...lld:pubmed
pubmed-article:9282824pubmed:meshHeadingpubmed-meshheading:9282824-...lld:pubmed
pubmed-article:9282824pubmed:meshHeadingpubmed-meshheading:9282824-...lld:pubmed
pubmed-article:9282824pubmed:meshHeadingpubmed-meshheading:9282824-...lld:pubmed
pubmed-article:9282824pubmed:meshHeadingpubmed-meshheading:9282824-...lld:pubmed
pubmed-article:9282824pubmed:meshHeadingpubmed-meshheading:9282824-...lld:pubmed
pubmed-article:9282824pubmed:meshHeadingpubmed-meshheading:9282824-...lld:pubmed
pubmed-article:9282824pubmed:meshHeadingpubmed-meshheading:9282824-...lld:pubmed
pubmed-article:9282824pubmed:meshHeadingpubmed-meshheading:9282824-...lld:pubmed
pubmed-article:9282824pubmed:meshHeadingpubmed-meshheading:9282824-...lld:pubmed
pubmed-article:9282824pubmed:year1997lld:pubmed
pubmed-article:9282824pubmed:articleTitleResponse of patients with dual hepatitis B virus and C virus infection to interferon therapy.lld:pubmed
pubmed-article:9282824pubmed:affiliationLiver Research Unit, Chang Gung Memorial Hospital, Chang Gung Medical College, Taipei, Taiwan.lld:pubmed
pubmed-article:9282824pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9282824pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9282824lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9282824lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9282824lld:pubmed